Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director, Pipeline & Product Communications will lead pipeline and product communications strategy and execution for one or more RAS(ON) inhibitors or tumor types, supporting programs from early clinical development through regulatory milestones and pre-launch readiness. This role is responsible for shaping how tumor-specific pipeline and product narratives are communicated to external stakeholders, including scientific and medical audiences, patients and advocates, and industry media. Reporting to the Senior Director, Pipeline & Product Communications, this role will partner closely with cross-functional teams, including R&D, Medical Affairs, Regulatory, Commercial, Market Access, Patient Advocacy, Legal, and Corporate Communications, to ensure clear, consistent, and differentiated communications for the assigned tumor area. This is a high-impact role for a communications professional who combines scientific fluency with strong executional rigor and cross-functional collaboration.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director